多非利特诱发的长QT间期和尖端扭转型室性心动过速。
Dofetilide-induced long QT and torsades de pointes.
作者信息
Aktas Mehmet K, Shah Abrar H, Akiyama Toshio
机构信息
University of Rochester, Strong Memorial Hospital, Department of Cardiovascular Diseases, Rochester, NY 14642, USA.
出版信息
Ann Noninvasive Electrocardiol. 2007 Jul;12(3):197-202. doi: 10.1111/j.1542-474X.2007.00161.x.
Abstract
Dofetilide, a new class III antiarrhythmic agent, has been approved as an antiarrhythmic agent for the treatment of atrial fibrillation and atrial flutter. Dofetilide selectively inhibits the rapid component of the delayed rectifier potassium current resulting in a prolongation of the effective refractory period. Like other drugs that affect potassium currents, the prolonged QT interval occurring in the patients treated with dofetilide can be complicated by torsades de pointes. We report four cases of dofetilide-induced QT prolongation and torsades de pointes. We discuss the risk factors for the development of dofetilide-induced long QT and torsades de pointes and review the current literature.
摘要
多非利特是一种新型III类抗心律失常药物，已被批准作为抗心律失常药用于治疗心房颤动和心房扑动。多非利特选择性抑制延迟整流钾电流的快速成分，导致有效不应期延长。与其他影响钾电流的药物一样，接受多非利特治疗的患者出现的QT间期延长可能会并发尖端扭转型室性心动过速。我们报告4例多非利特引起的QT延长和尖端扭转型室性心动过速病例。我们讨论多非利特引起长QT和尖端扭转型室性心动过速的危险因素，并综述当前文献。
相似文献
1
Dofetilide-induced long QT and torsades de pointes.多非利特诱发的长QT间期和尖端扭转型室性心动过速。
Ann Noninvasive Electrocardiol. 2007 Jul;12(3):197-202. doi: 10.1111/j.1542-474X.2007.00161.x.
2
Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.多非利特诱发尖端扭转型室性心动过速：机制、危险因素及管理策略。
Indian Heart J. 2014 Nov-Dec;66(6):640-8. doi: 10.1016/j.ihj.2013.12.021. Epub 2014 Jan 7.
3
Marked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking dofetilide for atrial fibrillation: a cautionary tale.一名老年男性因心房颤动服用多非利特后，继发于急性缺血的显著QT间期延长和尖端扭转型室速：一则警示故事。
J Cardiovasc Pharmacol Ther. 2005 Sep;10(3):191-5. doi: 10.1177/107424840501000307.
4
Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.住院房颤患者中与多非利特相关的尖端扭转型室速风险的潜在可改变因素。
J Interv Card Electrophysiol. 2019 Mar;54(2):189-196. doi: 10.1007/s10840-018-0476-2. Epub 2018 Oct 23.
5
Ibutilide-induced long QT syndrome and torsade de pointes.依布利特诱发的长QT综合征和尖端扭转型室性心动过速。
Am J Ther. 2002 Nov-Dec;9(6):527-9. doi: 10.1097/00045391-200211000-00013.
6
Frequency of toxicity with chemical conversion of atrial fibrillation with dofetilide.使用多非利特进行化学转化治疗心房颤动的毒性频率。
Am J Cardiol. 2013 Aug 15;112(4):505-8. doi: 10.1016/j.amjcard.2013.04.014. Epub 2013 May 22.
7
Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation.多非利特与美西律预防心房颤动的协同作用。
J Am Heart Assoc. 2017 May 18;6(5):e005482. doi: 10.1161/JAHA.117.005482.
8
Dofetilide: a new class III antiarrhythmic agent.多非利特：一种新型III类抗心律失常药物。
Expert Rev Cardiovasc Ther. 2007 Jan;5(1):9-19. doi: 10.1586/14779072.5.1.9.
9
Assessment of Sotalol and Dofetilide Dosing at a Large Academic Medical Center.大型学术医疗中心中索他洛尔和多非利特的剂量评估。
J Cardiovasc Pharmacol Ther. 2020 Sep;25(5):438-443. doi: 10.1177/1074248420921740. Epub 2020 Apr 29.
10
Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome.快速延迟整流电流激活剂在获得性长QT综合征兔模型中的抗心律失常特性
Cardiovasc Res. 2008 Jul 1;79(1):61-9. doi: 10.1093/cvr/cvn075. Epub 2008 Mar 26.
引用本文的文献
1
Establishment and validation of a torsade de pointes prediction model based on human iPSC‑derived cardiomyocytes.基于人诱导多能干细胞衍生心肌细胞的尖端扭转型室速预测模型的建立与验证
Exp Ther Med. 2022 Dec 9;25(1):61. doi: 10.3892/etm.2022.11760. eCollection 2023 Jan.
2
Evaluation of the Impact of an Institution-Specific Dofetilide Initiation Protocol on Mean Hospital Length of Stay and Cost for Dofetilide Initiation.评估特定机构的多非利特起始治疗方案对多非利特起始治疗的平均住院时长和费用的影响。
Pharmacoecon Open. 2019 Mar;3(1):119-126. doi: 10.1007/s41669-018-0077-0.
3
Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation.多非利特与美西律预防心房颤动的协同作用。
J Am Heart Assoc. 2017 May 18;6(5):e005482. doi: 10.1161/JAHA.117.005482.
4
Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.老年患者药物性尖端扭转型室速中QT间期延长剂的鲁莽使用。
Z Gerontol Geriatr. 2018 Jan;51(1):41-47. doi: 10.1007/s00391-016-1155-5. Epub 2016 Nov 22.
5
Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.多非利特诱发尖端扭转型室性心动过速：机制、危险因素及管理策略。
Indian Heart J. 2014 Nov-Dec;66(6):640-8. doi: 10.1016/j.ihj.2013.12.021. Epub 2014 Jan 7.
6
In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials.二氢青蒿素-哌喹复方制剂与其他抗疟药的体外心血管效应比较。
Antimicrob Agents Chemother. 2012 Jun;56(6):3261-70. doi: 10.1128/AAC.05688-11. Epub 2012 Mar 5.
本文引用的文献
1
Phase IV trial evaluating the effectiveness and safety of dofetilide.评估多非利特有效性和安全性的IV期试验。
Ann Pharmacother. 2004 Jul-Aug;38(7-8):1142-7. doi: 10.1345/aph.1D465. Epub 2004 May 25.
2
A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia.一项关于口服多非利特与口服索他洛尔对缺血性心脏病合并持续性室性心动过速患者血流动力学影响的随机交叉研究。
Eur J Clin Pharmacol. 2002 Jun;58(3):165-9. doi: 10.1007/s00228-002-0464-3. Epub 2002 May 4.
3
Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy.多非利特治疗左心室功能减退患者心房颤动-扑动的疗效：丹麦多非利特心律失常和死亡率研究（DIAMOND）子研究
Circulation. 2001 Jul 17;104(3):292-6. doi: 10.1161/01.cir.104.3.292.
4
Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo.多非利特预防阵发性室上性心动过速症状性发作的疗效和安全性：与普罗帕酮和安慰剂的6个月双盲比较。
Am Heart J. 2001 Jul;142(1):93-8. doi: 10.1067/mhj.2001.115439.
5
Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure.静脉注射多非利特对心力衰竭患者的心脏及血流动力学影响
Am J Cardiol. 2001 Jun 1;87(11):1250-4. doi: 10.1016/s0002-9149(01)01514-4.
6
Qtc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide.QTc间期作为一种指导，用于选择那些患有充血性心力衰竭且左心室收缩功能降低、将从多非利特抗心律失常治疗中获益的患者。
Circulation. 2001 Mar 13;103(10):1422-7. doi: 10.1161/01.cir.103.10.1422.
7
Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial.决奈达隆对近期心肌梗死合并左心室功能不全患者的影响：一项随机试验。
Lancet. 2000 Dec 16;356(9247):2052-8. doi: 10.1016/s0140-6736(00)03402-4.
8
Cardiovascular drugs. Dofetilide.心血管药物。多非利特。
Circulation. 2000 Nov 21;102(21):2665-70. doi: 10.1161/01.cir.102.21.2665.
9
Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.口服多非利特在慢性心房颤动或心房扑动患者转复并维持窦性心律中的疗效与安全性：多非利特症状性心房颤动研究（SAFIRE-D）
Circulation. 2000 Nov 7;102(19):2385-90. doi: 10.1161/01.cir.102.19.2385.
10
Dofetilide: a new pure class III antiarrhythmic agent.多非利特：一种新型的单纯Ⅲ类抗心律失常药物。
Am Heart J. 2000 Nov;140(5):697-706. doi: 10.1067/mhj.2000.110457.
Zotero 插件